VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: E'Lane who wrote (9289)	6/7/1998 2:29:00 PM
From: Sal Milani	Read Replies (1) of 23519

E'Lane - <I wish I could help you out.> Thanks anyway. It was a very good post and the author, whoever he/she is, arrives at approx. the same numbers as I. The biggest difference is in the MUSE revenues per year per user. I took an arbitrary $5/week * 50 weeks for $250/yr whereas he/she uses 36 times/yr * $22/dose = $792/yr. I think the revenues to Vivus are only about $12/dose and I expect it to come down since Viagra's retail price is only about $8. Anyway it looks like Vivus should be able to keep busy in spite of Viagra.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next